Population-Based Prevalence of Cancer Family History in Southeastern Iran

Q3 Medicine
Bita Karimi, M. Baneshi, A. Haghdoost, H. Molavi Vardanjani, J. Ostovarfar
{"title":"Population-Based Prevalence of Cancer Family History in Southeastern Iran","authors":"Bita Karimi, M. Baneshi, A. Haghdoost, H. Molavi Vardanjani, J. Ostovarfar","doi":"10.5812/semj-128068","DOIUrl":null,"url":null,"abstract":"Background: Cancer family history (CFH) could be an effective non-invasive preventive tool for cancer screening. There are limited data on the prevalence of CFH. Objectives: We aimed to estimate a robust population-based prevalence of CFH in southeastern Iran. Methods: This study is a population-based survey. Participants were recruited in a multistage proportional-to-size cluster sampling design. A validated interview form was used, including a pedigree table and a cancer detail table. A positive CFH was defined as a verbal self-report of cancer diagnosis in at least 1 relative. The CFH prevalence was estimated according to age, gender, residential area, relatives’ closeness, and cancer type. Estimated prevalence values were corrected for the sensitivity of self-reported CFH in a Monte Carlo-based sensitivity analysis. Results: A total of 2057 interviews with a male-female ratio of 1: 14 were analyzed. The overall prevalence (95% uncertainty level (UL)) of CFH in at least 1 relative (first or second-degree relatives (FDR/SDR)) was 37.06 (27.50, 47.05). The prevalence (95% UL) of CFH in at least 1 female and male FDR was 12.54 (8.62, 17.25) and 11.07 (7.22, 15.34), respectively. The prevalence (95% UL) of a positive history of lung, breast, and colorectal cancers in at least 1 FDR was 2.05 (1.36, 2.90), 1.36 (0.79, 2.08), and 1.23 (0.63, 2.02), respectively. Conclusions: The prevalence of positive CFH in FDRs is less than that of developed countries and exceeds 11.8% in the general population of southeastern Iran. CFH taken by general practitioners in routine visits is recommended as a screening tool in this population.","PeriodicalId":39157,"journal":{"name":"Shiraz E Medical Journal","volume":"26 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Shiraz E Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/semj-128068","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cancer family history (CFH) could be an effective non-invasive preventive tool for cancer screening. There are limited data on the prevalence of CFH. Objectives: We aimed to estimate a robust population-based prevalence of CFH in southeastern Iran. Methods: This study is a population-based survey. Participants were recruited in a multistage proportional-to-size cluster sampling design. A validated interview form was used, including a pedigree table and a cancer detail table. A positive CFH was defined as a verbal self-report of cancer diagnosis in at least 1 relative. The CFH prevalence was estimated according to age, gender, residential area, relatives’ closeness, and cancer type. Estimated prevalence values were corrected for the sensitivity of self-reported CFH in a Monte Carlo-based sensitivity analysis. Results: A total of 2057 interviews with a male-female ratio of 1: 14 were analyzed. The overall prevalence (95% uncertainty level (UL)) of CFH in at least 1 relative (first or second-degree relatives (FDR/SDR)) was 37.06 (27.50, 47.05). The prevalence (95% UL) of CFH in at least 1 female and male FDR was 12.54 (8.62, 17.25) and 11.07 (7.22, 15.34), respectively. The prevalence (95% UL) of a positive history of lung, breast, and colorectal cancers in at least 1 FDR was 2.05 (1.36, 2.90), 1.36 (0.79, 2.08), and 1.23 (0.63, 2.02), respectively. Conclusions: The prevalence of positive CFH in FDRs is less than that of developed countries and exceeds 11.8% in the general population of southeastern Iran. CFH taken by general practitioners in routine visits is recommended as a screening tool in this population.
伊朗东南部基于人群的癌症家族史患病率
背景:癌症家族史(CFH)可能是一种有效的非侵入性癌症筛查预防工具。关于CFH患病率的数据有限。目的:我们旨在估计伊朗东南部以人群为基础的CFH患病率。方法:本研究采用基于人群的调查方法。参与者被招募在一个多阶段的比例大小的集群抽样设计。使用了一个经过验证的访谈表,包括一个谱系表和一个癌症详细信息表。CFH阳性定义为至少有1名亲属口头自我报告癌症诊断。根据年龄、性别、居住区域、亲属亲密程度和癌症类型估计CFH患病率。在蒙特卡洛敏感性分析中,对自我报告CFH的敏感性进行了估计患病率值的校正。结果:共分析了2057份男女比例为1:14的访谈。至少1个亲属(一级或二级亲属(FDR/SDR)) CFH的总体患病率(95%不确定水平(UL))为37.06(27.50,47.05)。至少1例FDR患者CFH患病率(95% UL)分别为12.54(8.62,17.25)和11.07(7.22,15.34)。在至少1次FDR中,肺癌、乳腺癌和结直肠癌阳性病史的患病率(95% UL)分别为2.05(1.36,2.90)、1.36(0.79,2.08)和1.23(0.63,2.02)。结论:伊朗东南部fdr地区CFH阳性率低于发达国家,在伊朗东南部一般人群中超过11.8%。建议全科医生在常规就诊时进行CFH检查,作为该人群的筛查工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Shiraz E Medical Journal
Shiraz E Medical Journal Medicine-Medicine (all)
CiteScore
1.00
自引率
0.00%
发文量
63
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信